Phaseline

Companies › TRB Chemedica

TRB Chemedica: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Diacerein (Artrodar)
Anti-catabolic agent; inhibits interleukin-1 (IL-1) production and cartilage degradation
–Phase 3Knee OsteoarthritisDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04318041Diacerein (Artrodar)Phase 3Knee OsteoarthritisImmunologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals Fujian Mindong Rejuvenation Pharmaceutical Jiangsu Genscend Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.